A study showed that the combination of anti-PD-L1 and anti-CTLA-L1 in patients with recurrent or metastatic HNSCC, compared to anti-PD-L1 therapy alone, is more likely to affect tumor progression [66]. Here, CD274 is linked to neoplasm.